With CIPN, everyday tasks can become never-y day tasks

Nerve damage can make hands-on
experiences excruciating.1

Be a part of our mission to empower patients—complete a 6-question survey. Athenex Oncology will make a charitable donation to a MBC organization.

Take the survey

Image of a person driving with barbed wire around their hands to show how CIPN and nerve damage can make everyday tasks difficult and painful

References

  1. Han Y, Smith TM. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol. 2013;4:156.

  2. Serenty M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155:2461-2470.

  3. Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75(4):659-670.

  4. Starobova H, et al. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174.

  5. Kolb NA, Smith AG, Singleton JR, et al. Chemotherapy induced peripheral neuropathy symptoms and fall risk. JAMA Neurol. 2016;73(7):860-866.

  6. Winters-Stone KM, et al. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;35(23):2604-2612

  7. Mongiovi JM, et al. Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res. 2018;20(1):146.

  8. Burton AW, et al. Chronic pain in the cancer survivor: a new frontier. Pain Med. 2007;8(2):189-198.

  9. Loprinzi CL, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29(11): 1472-1478.

  10. Reeves BN, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy; North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118(20):5171-5178.

  11. Schneider BP, et al. Genetic associations with taxane-induced neuropathy by a genomewide association study (GWAS) in E5103. J Clin Oncol. 2011;29(suppl):1000. doi:10.1200/jco.2011.29.15_suppl.1000.

  12. Bao T, et al. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327-333.

  13. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24(10):1633-1642.

  14. Hou S, et al. Treatment of chemotherapy-induced peripheral neuropathy: systematic review and recommendations. Pain Physician. 2018;21:571-592.

  15. Stubblefield MD, Burstein HJ, Burton AW, et al. NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009;7 (suppl
 5):S1-S26.